8 / 11
Page 44
Volume 03
Stem Cells 2019 & Pediatrics Congress 2019
November 06-07, 2019
Journal of Child and Adolescent Psychiatry
November 06-07, 2019 | Tokyo, Japan
STEM CELLS AND REGENERATIVE MEDICINE
PEDIATRICS AND CHILD CARE
International Conference on
2
nd
World Congress on
&
J Child Adolesc Psych, Volume 03
Stem cell therapy for the treatment of severe tissue damage after radiation exposure
Alain Chapel
Institute of Radiological Protection and Nuclear Safety, France
T
he late adverse effects of pelvic radiotherapy concern 5 to 10% of them, which could be life threatening. However, a clear
medical consensus concerning the clinical management of such healthy tissue sequelae does not exist. Our group has
demonstrated in preclinical animal models that systemic MSC injection is a promise approach for the medical management of
gastrointestinal disorder after irradiation. We have shown that MSC migrate to damaged tissues and restore gut functions after
irradiation.
The clinical status of four first patients suffering from severe pelvic side effects resulting from an over-dosage was improved
following MSC injection in a compassional situation. A quantity of 2x106 - 6x106 MSC/kg were infused intravenously to the
patients. Pain, hemorrhage, frequency of diarrheas and fistulisation as well as the lymphocyte subsets in peripheral blood were
evaluated before MSC therapy and during the follow-up. Two patients revealed a substantiated clinical response for pain and
hemorrhage after MSC therapy. In one patient pain reappeared after 6 months and again substantially responded on a second
MSC infusion. A beginning fistulisation process could be stopped in one patient resulting in a stable remission for more than
3 years of follow-up. The frequency of painful diarrhea diminished from an average of 6/d to 3/d after the first and 2/d after
the 2nd MSC injection in one patient. In all patients, prostate cancer remained in stable complete remission. A modulation of
the lymphocyte subsets towards a regulatory pattern and diminution of activated T cells accompanies the clinical response in
refractory irradiation-induced colitis. No toxicity occurred.
MSC therapy was safe and effective on pain, diarrhea, haemorrhage, inflammation, fibrosis and limited fistulisation. For patients
with refractory chronic inflammatory and fistulising bowel diseases, systemic MSC injections represent a safe option for salvage
therapy. A clinical phase II trial will start in 2019.
alain.chapel@irsn.fr